天士力：全资子公司注射用重组人尿激酶原增加急性缺血性脑卒中新适应症获得药品注册证书

Core Viewpoint - Tianjin Tasly Pharmaceutical Co., Ltd. announced the approval of a new indication for its innovative biological drug, recombinant human urokinase (Puyouke), for thrombolytic treatment of acute ischemic stroke by the National Medical Products Administration [1] Group 1 - The company received a drug registration certificate for the new indication [1] - The drug has independent intellectual property rights [1] - The new application is specifically for the treatment of acute ischemic stroke [1]